Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010; 8: 793 802. 120. Dussol B, Moussi-Frances J, Morange S et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005; 20: 349 353. 121. Musini VM, Wright JM, Bassett K et al. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2009: CD003825. 122. Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol 2009; 53: 379 387. 123. Frishman WH, Alwarshetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 2002; 41: 505 516. 124. Ram CV. Beta-blockers in hypertension. Am J Cardiol 2010; 106: 1819 1825. 125. Oregon Health Resources Commission. Beta Adrenergic Blockers Pharma- ceutical Subcommittee Report. Update #3, March 2008. 126. Badve SV, Roberts MA, Hawley CM et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 1152 1161. 127. Chen JM, Heran BS, Perez MI et al. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev 2010: CD007185. 128. Ritz E, Rump LC. Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury? Curr Hypertens Rep 2007; 9: 409 414. 129. Sica DA, Gehr TW. Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens 2003; 12: 123 131. 130. Bakris GL, Weir MR, Secic M et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65: 1991 2002. 131. Oregon Health Resources Commission. 